Clinical Observation of Neutropenia Patients with Hematonosis Treated with Polymyxin B Sulfate.
10.19746/j.cnki.issn.1009-2137.2022.05.046
- Author:
Shun-Quan WU
1
;
Rong ZHAN
2
Author Information
1. Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China.
2. Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China E-mail: deanzhanrong@qq.com.
- Publication Type:Journal Article
- Keywords:
febrile neutropenia;
hematonosis;
polymyxin B sulfate
- MeSH:
Anti-Bacterial Agents/therapeutic use*;
Carbapenems;
Febrile Neutropenia/drug therapy*;
Humans;
Polymyxin B/therapeutic use*;
Tigecycline
- From:
Journal of Experimental Hematology
2022;30(5):1596-1600
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical efficacy and safety of polymyxin B sulfate in febrile neutropenia patients with hematonosis.
METHODS:Clinical data of 50 patients in the department of hematology, Fujian Medical University Union Hospital from October 2019 to September 2020 were collected. All the patients developed febrile neutropenia after chemotherapy or hematopoietic stem cell transplantation. According to the results of drug susceptible test, polymyxin B sulfate was administrated mainly when the empirical antimicrobial treatments was poor and the pathogenic microbes test was positive.
RESULTS:A total of 85 times of infection occurred in 50 patients. The infection sites were lung, blood flow, intestinal tract, oral cavity, perianal, soft tissue and nasal cavity. Gram negative bacteria was the main pathogenic microbe. After administration of polymyxin B sulfate when the etiology was confirmed, the total effective rate was 68%, especially the effective rate increased significantly after more than 7 days of polymyxin B sulfate treatment. Also, 24% and 8% of the patients were discharged automatically and died respectively. The effective rate of patients receiving carbapenem antibiotics changed to polymyxin B sulfate within 14 or 7 days was 80% and 70.6%, respectively, while the effective rate of patients who changed after 2 weeks was only 33.3%. The effective rate of patients receiving tigecycline changed to polymyxin B sulfate within 14 or 7 days was 80% and 66.7%, respectively. The incidence of adverse reactions of polymyxin B sulfate was low, most of which were mild, and only one patient occurred rhabdomyolysis.
CONCLUSION:Polymyxin B sulfate has good clinical efficacy and safety in febrile neutropenia patients with hematonosis.
